Antihypertensive Market size is expected to grow at a CAGR of 3.24% throughout the forecast period, reaching nearly US$ 31.58 Bn. by 2029. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.To know about the Research Methodology :- Request Free Sample Report Hypertension is a chronic condition associated with abnormal blood pressure elevation in both diastolic and systolic. Hypertension is highly associated with premature death worldwide and is a key concern in public health in both developing and developed countries. The anti-hypertension drugs are used for leveling or reducing blood pressure. In 2021, the prevalence of hypertension was estimated to be more than 38% of adults worldwide, which has increased by 5% globally between 2021 and 2029. It is also observed that the prevalence rate has decreased by 2.4% in developed countries, but has increased in low as well as middle-income countries because of obstacles and limited resources in healthcare delivery. There is also a need for stringent measures to prevent, treat and control hypertension along with improving awareness for boosting the global anti-hypertensive market. A global antihypertensive market is driven by factors such as the high prevalence of hypertension associated with lifestyle changes, unhealthy diet, and aging irrespective of demography. In addition, the anti-hypertension market has also shown tremendous growth due to the increase in the patient pool, and rise in geriatric population. Moreover, the extensive research and development for the development of novel pipeline drug are further expected to fuel global anti hypertension market in the current forecast period. The global antihypertensive market is segmented into therapeutic class, and geography. Among the therapeutic class, angiotensin-converting enzyme (ACE) inhibitors segment accounted for the largest share of the market in 2021, due to the vastly preferred first line of action by geriatric population and high action mechanism. All these therapeutic classes have shown a huge effect in reducing cardiovascular mortality and morbidity, with these drugs being either administered solely or in combination depending upon the severity of hypertension. On the basis of region, a global antihypertensive market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In the year 2021, North America accounted for the largest share of the antihypertensive market followed by Europe, and the Asia Pacific. North American domination is mainly because of the increased prevalence of hypertension and another cardiovascular disease as well as people getting more aware of hypertension and its consequences. Also, it is the presence of major manufacturers together with their well-established network in the region that have further helped in the overall growth of the global antihypertensive market. Asia Pacific region is also expected to see growth in the antihypertensive market during the forecast period because of the rising awareness related to hypertension and its complications. The objective of the report is to present comprehensive Global Antihypertensive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Antihypertensive Market North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the Global Antihypertensive Market North America for Asia Pacific size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Antihypertensive Market North America for Asia Pacific make the report investor’s guide.
Antihypertensive Market Scope: Inquire before Buying
Antihypertensive Market, By Therapeutic class: • Diuretics, • Angiotensin Converting Enzyme (ACE) Inhibitors, • Angiotensin Receptor Blockers (ARBs), • Beta Blockers, Direct Renin Inhibitors, • Calcium Channel Blockers, • OthersAntihypertensive Market, by Region:
• North America • Europe • Asia Pacific • The Middle East and Africa • South AmericaAntihypertensive Market Key Players:
• Novartis • Sanofi • Merck • Boehringer Ingelheim • Lupin • Johnson Johnson • Astra Zeneca • Daiichi Sankyo • Ranbaxy • ctelion • Alvogen • Bayer • Bellerophon Therapeutics • Boryung Pharmaceutical • CJ Healthcare • Gilead • Eli Lilly • HanAll Biopharma • Hanmi Pharmaceutical • JW Pharmaceutical • Kitov Pharmaceuticals • Kyowa Hakko Kirin • Lung Biotechnology • Nippon Shinyaku • Pfizer, Inc. Frequently Asked Questions: 1. Which region has the largest share in Global Antihypertensive Market? Ans: North America region holds the highest share in 2021. 2. What is the growth rate of Global Antihypertensive Market? Ans: The Global Antihypertensive Market is growing at a CAGR of 3.24% during forecasting period 2022-2029. 3. What is scope of the Global Antihypertensive market report? Ans: Global Antihypertensive Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Antihypertensive market? Ans: The important key players in the Global Antihypertensive Market are – Novartis, Sanofi, Merck, Boehringer Ingelheim, Lupin, Johnson Johnson, Astra Zeneca, Daiichi Sankyo, Ranbaxy, ctelion, Alvogen, Bayer, Bellerophon Therapeutics, Boryung Pharmaceutical, CJ Healthcare, Gilead, Eli Lilly, HanAll Biopharma, Hanmi Pharmaceutical, JW Pharmaceutical, Kitov Pharmaceuticals, Kyowa Hakko Kirin, Lung Biotechnology, Nippon Shinyaku, Pfizer, and Inc. 5. What is the study period of this market? Ans: The Global Antihypertensive Market is studied from 2021 to 2029.
Global Antihypertensive Market
1. INTRODUCTION 1.1 Market description & Scope ((2021-2029)) 1.2 Objectives 1.2.1 Key Takeaways 1.2.2 Abbreviations & Acronyms 2. RESEARCH METHODOLOGY 2.1 Methods used for market forecasting 2.2 Data Sources 2.2.1 Paid Databases 2.2.2 Primary Sources 2.2.3 Secondary Sources 3. EXECUTIVE SUMMARY 3.1 Major Findings 3.1.1 Key Segment Trends 3.1.1.1 Therapeutic Class 3.1.2 Key Regional Trends 3.2 Key Companies and their Strategies 4. MARKET OVERVIEW 4.1 Antihypertensive Concept & Definition 4.2 Segments Overview 4.2.1 By Therapeutic class 4.2.1.1 Diuretics 4.2.1.2 Angiotensin Converting Enzyme (ACE) Inhibitors 4.2.1.3 Angiotensin Receptor Blockers (ARBs) 4.2.1.4 Beta Blockers 4.2.1.5 Direct Renin Inhibitors 4.2.1.6 Calcium Channel Blockers 4.2.1.7 Others 4.3 Market Dynamics 4.3.1 Drivers 4.3.2 Restraints 4.3.3 Opportunities 4.4 Porter’s Analysis 4.5 PESTLE Analysis 4.6 Fragmentation 4.6.1 Key strategic Alliances of companies (inorganic & organic) 4.6.2 Company Market Share (Top 10 Players) 4.6.3 Comparative Analysis of Key players in Artificial Intelligence 4.7 Key Trends 4.8 Key Trends in Global Antihypertensive Market 5. GLOBAL ANTIHYPERTENSIVE THERAPEUTIC CLASS ESTIMATES & TREND ANALYSIS (2021-2029) 5.1 Global Antihypertensive Market: Therapeutic Class Analysis 5.1.1 Diuretics 5.1.1.1 Market Share and growth forecasts, (2021-2029)(USD Billion) 5.1.2 Angiotensin Converting Enzyme (ACE) Inhibitors 5.1.2.1 Market Share and growth forecasts, (2021-2029)(USD Billion) 5.1.3 Angiotensin Receptor Blockers (ARBs) 5.1.3.1 Market Share and growth forecasts, (2021-2029)(USD Billion) 5.1.4 Beta Blockers 5.1.4.1 Market Share and growth forecasts, (2021-2029)(USD Billion) 5.1.5 Direct Renin Inhibitors 5.1.5.1 Market Share and growth forecasts, (2021-2029)(USD Billion) 5.1.6 Calcium Channel Blockers 5.1.6.1 Market Share and growth forecasts, (2021-2029)(USD Billion) 5.1.7 Others 5.1.7.1 Market Share and growth forecasts, (2021-2029)(USD Billion) 5.2 Global Antihypertensive Market: Therapeutic Class Trends 6. REGIONAL ESTIMATES & TREND ANALYSIS (2021-2029) 6.1 Global Antihypertensive Market share by Region, 2021 & 2029 6.2 North America 6.2.1 North America Antihypertensive, Market Share and growth forecasts, 2021-2029 (USD Billion) 6.2.2 Antihypertensive Drivers for North America Market 6.2.3 Market Share Analysis and Growth Forecast, by Country 6.2.3.1 US 6.2.3.2 Canada 6.2.3.3 Rest of North America 6.2.4 Country-wise GDP Growth Forecast 6.2.5 Antihypertensive Trends In North America Market 6.3 Europe 6.3.1 Europe Antihypertensive, Market Share and growth forecasts, (2021-2029)(USD Billion) 6.3.2 Antihypertensive Drivers for Europe Market 6.3.3 Market Share Analysis and Growth Forecast, by Country 6.3.3.1 UK 6.3.3.2 Germany 6.3.3.3 Italy 6.3.3.4 France 6.3.3.5 Rest of Europe 6.3.4 Country-wise GDP Growth Forecast 6.3.5 Antihypertensive Trends in Europe Market 6.4 Asia Pacific 6.4.1 Asia Pacific Antihypertensive, Market Share and growth forecasts, (2021-2029)(USD Billion) 6.4.2 Antihypertensive Drivers for Asia Pacific Market 6.4.3 Market Share Analysis and Growth Forecast, by Country 6.4.3.1 China 6.4.3.2 Japan 6.4.3.3 India 6.4.3.4 Australia 6.4.3.5 Rest of Asia Pacific 6.4.4 Country-wise GDP Growth Forecast 6.4.5 Antihypertensive Trends in Asia Pacific Market 6.5 Latin America 6.5.1 Latin America Antihypertensive, Market Share and growth forecasts, (2021-2029)(USD Billion) 6.5.2 Antihypertensive Drivers for Latin America Market 6.5.3 Market Share Analysis and Growth Forecast, by Country 6.5.3.1 Brazil 6.5.3.2 Mexico 6.5.3.3 Rest of Latin America 6.5.4 Country-wise GDP Growth Forecast 6.5.5 Antihypertensive Trends in Latin America Market 6.6 Middle East & Africa 6.6.1 Middle East & Africa Antihypertensive, Market Share and growth forecasts, (2021-2029)(USD Billion) 6.6.2 Antihypertensive Drivers for Middle East & Africa Market 6.6.3 Market Share Analysis and Growth Forecast, by Country 6.6.3.1 GCC 6.6.3.2 South Africa 6.6.3.3 Rest of Middle East & Africa 6.6.4 Country-wise GDP Growth Forecast 6.6.5 Antihypertensive Trends in Middle East & Africa Market 7. MARKET SHARE ANALYSIS 7.1 Key Players Regional Market share Analysis 7.1.1 US 7.1.2 Canada 7.1.3 UK 7.1.4 Germany 7.1.5 Italy 7.1.6 France 7.1.7 China 7.1.8 Japan 7.1.9 India 8. MARKET COMPETITION ANALYSIS 8.1 Strategy Framework 8.2 Consolidation 8.2.1 Patent Analysis 8.2.2 Mergers & Acquisitions 8.2.2.1 Product Based 8.2.2.2 Services Based 8.2.2.3 Region Based 8.2.2.4 List of Mergers & Acquisitions 8.2.3 Company Benchmarking (Revenue & Profit Based) 8.2.4 Strategic Assessment of Company Consolidations 8.2.5 Emerging Business Models 8.3 Company Profiles 8.3.1 Novartis 8.3.1.1 Company overview 8.3.1.2 Key financials 8.3.1.3 Geographical presence 8.3.1.4 Product and Business Segments 8.3.1.5 Strategic initiatives 8.3.1.6 SWOT analysis 8.3.1.7 Competitive positioning and landscape 8.3.2 Sanofi 8.3.2.1 Company overview 8.3.2.2 Key financials 8.3.2.3 Geographical presence 8.3.2.4 Product and Business Segments 8.3.2.5 Strategic initiatives 8.3.2.6 SWOT analysis 8.3.2.7 Competitive positioning and landscape 8.3.3 Merck 8.3.3.1 Company overview 8.3.3.2 Key financials 8.3.3.3 Geographical presence 8.3.3.4 Product and Business Segments 8.3.3.5 Strategic initiatives 8.3.3.6 SWOT analysis 8.3.3.7 Competitive positioning and landscape 8.3.4 Boehringer Ingelheim 8.3.4.1 Company overview 8.3.4.2 Key financials 8.3.4.3 Geographical presence 8.3.4.4 Product and Business Segments 8.3.4.5 Strategic initiatives 8.3.4.6 SWOT analysis 8.3.4.7 Competitive positioning and landscape 8.3.5 Lupin 8.3.5.1 Company overview 8.3.5.2 Key financials 8.3.5.3 Geographical presence 8.3.5.4 Product and Business Segments 8.3.5.5 Strategic initiatives 8.3.5.6 SWOT analysis 8.3.5.7 Competitive positioning and landscape 8.3.6 Johnson Johnson 8.3.6.1 Company overview 8.3.6.2 Key financials 8.3.6.3 Geographical presence 8.3.6.4 Product and Business Segments 8.3.6.5 Strategic initiatives 8.3.6.6 SWOT analysis 8.3.6.7 Competitive positioning and landscape 8.3.7 Astra Zeneca 8.3.7.1 Company overview 8.3.7.2 Key financials 8.3.7.3 Geographical presence 8.3.7.4 Product and Business Segments 8.3.7.5 Strategic initiatives 8.3.7.6 SWOT analysis 8.3.7.7 Competitive positioning and landscape 8.3.8 Daiichi Sankyo 8.3.8.1 Company overview 8.3.8.2 Key financials 8.3.8.3 Geographical presence 8.3.8.4 Product and Business Segments 8.3.8.5 Strategic initiatives 8.3.8.6 SWOT analysis 8.3.8.7 Competitive positioning and landscape 8.3.9 Ranbaxy 8.3.9.1 Company overview 8.3.9.2 Key financials 8.3.9.3 Geographical presence 8.3.9.4 Product and Business Segments 8.3.9.5 Strategic initiatives 8.3.9.6 SWOT analysis 8.3.9.7 Competitive positioning and landscape 8.3.10 ctelion 8.3.10.1 Company overview 8.3.10.2 Key financials 8.3.10.3 Geographical presence 8.3.10.4 Product and Business Segments 8.3.10.5 Strategic initiatives 8.3.10.6 SWOT analysis 8.3.10.7 Competitive positioning and landscape 8.3.11 Alvogen 8.3.11.1 Company overview 8.3.11.2 Key financials 8.3.11.3 Geographical presence 8.3.11.4 Product and Business Segments 8.3.11.5 Strategic initiatives 8.3.11.6 SWOT analysis 8.3.11.7 Competitive positioning and landscape 8.3.12 Bellerophon Therapeutics 8.3.12.1 Company overview 8.3.12.2 Key financials 8.3.12.3 Geographical presence 8.3.12.4 Product and Business Segments 8.3.12.5 Strategic initiatives 8.3.12.6 SWOT analysis 8.3.12.7 Competitive positioning and landscape 8.3.13 Boryung Pharmaceutical 8.3.13.1 Company overview 8.3.13.2 Key financials 8.3.13.3 Geographical presence 8.3.13.4 Product and Business Segments 8.3.13.5 Strategic initiatives 8.3.13.6 SWOT analysis 8.3.13.7 Competitive positioning and landscape 8.3.14 CJ Healthcare 8.3.14.1 Company overview 8.3.14.2 Key financials 8.3.14.3 Geographical presence 8.3.14.4 Product and Business Segments 8.3.14.5 Strategic initiatives 8.3.14.6 SWOT analysis 8.3.14.7 Competitive positioning and landscape 8.3.15 Gilead 8.3.15.1 Company overview 8.3.15.2 Key financials 8.3.15.3 Geographical presence 8.3.15.4 Product and Business Segments 8.3.15.5 Strategic initiatives 8.3.15.6 SWOT analysis 8.3.15.7 Competitive positioning and landscape 8.3.16 Eli Lilly 8.3.16.1 Company overview 8.3.16.2 Key financials 8.3.16.3 Geographical presence 8.3.16.4 Product and Business Segments 8.3.16.5 Strategic initiatives 8.3.16.6 SWOT analysis 8.3.16.7 Competitive positioning and landscape 8.3.17 HanAll Biopharma 8.3.17.1 Company overview 8.3.17.2 Key financials 8.3.17.3 Geographical presence 8.3.17.4 Product and Business Segments 8.3.17.5 Strategic initiatives 8.3.17.6 SWOT analysis 8.3.17.7 Competitive positioning and landscape 8.3.18 Hanmi Pharmaceutical 8.3.18.1 Company overview 8.3.18.2 Key financials 8.3.18.3 Geographical presence 8.3.18.4 Product and Business Segments 8.3.18.5 Strategic initiatives 8.3.18.6 SWOT analysis 8.3.18.7 Competitive positioning and landscape 8.3.19 JW Pharmaceutical 8.3.19.1 Company overview 8.3.19.2 Key financials 8.3.19.3 Geographical presence 8.3.19.4 Product and Business Segments 8.3.19.5 Strategic initiatives 8.3.19.6 SWOT analysis 8.3.19.7 Competitive positioning and landscape 8.3.20 Kitov Pharmaceuticals 8.3.20.1 Company overview 8.3.20.2 Key financials 8.3.20.3 Geographical presence 8.3.20.4 Product and Business Segments 8.3.20.5 Strategic initiatives 8.3.20.6 SWOT analysis 8.3.20.7 Competitive positioning and landscape 8.3.21 Kyowa Hakko Kirin 8.3.21.1 Company overview 8.3.21.2 Key financials 8.3.21.3 Geographical presence 8.3.21.4 Product and Business Segments 8.3.21.5 Strategic initiatives 8.3.21.6 SWOT analysis 8.3.21.7 Competitive positioning and landscape 8.3.22 Lung Biotechnology 8.3.22.1 Company overview 8.3.22.2 Key financials 8.3.22.3 Geographical presence 8.3.22.4 Product and Business Segments 8.3.22.5 Strategic initiatives 8.3.22.6 SWOT analysis 8.3.22.7 Competitive positioning and landscape 8.3.23 Nippon Shinyaku 8.3.23.1 Company overview 8.3.23.2 Key financials 8.3.23.3 Geographical presence 8.3.23.4 Product and Business Segments 8.3.23.5 Strategic initiatives 8.3.23.6 SWOT analysis 8.3.23.7 Competitive positioning and landscape 8.3.24 Pfizer, Inc. 8.3.24.1 Company overview 8.3.24.2 Key financials 8.3.24.3 Geographical presence 8.3.24.4 Product and Business Segments 8.3.24.5 Strategic initiatives 8.3.24.6 SWOT analysis 8.3.24.7 Competitive positioning and landscape